Stock Evaluator: Liquidia Corporation (LQDA)

Liquidia Corporation LQDA

$57.41 -0.71 -1.22%
November 13, 2026 4:00:00 PM EST November 10, 2021 Volume: 1,932,416
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Commentary & Analysis


Financial Summary

Share Statistics LQDA Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $5,168.5 $447.9 68%
Shares Out (Mil) 89.5 46.7 59%
Institutional Ownership 88.1% 80.9% 56%
Float (Mil) 65.8 46.8 52%
Beta 0.41 0.74 22%
Avg Daily Volume (000s) 2,692 342 83%
Price Change
(52-week)
102.6% 54.7% 96%
Growth LQDA Industry
Median
Percentile
(All Stocks)
Sales (5yr) 195.7% 6.1% 100%
Net Income (5yr) (2.9%) (1.6%) 36%
EPS (5yr) 14.6% 15.0% 55
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (5.6%) (15.1%) 60%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 2 2 4
Current EPS $1.130 $0.075 $3.435
Month Ago EPS $0.372 $2.495 $2.318
# Rev Up 0 2 1
# Rev Down 2 0 0
Three Months Ago EPS $1.107 $3.297 $6.093
Year/Year Chg (142.8%) (109.4%) (546.9%)
Financials LQDA Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $622 $303 43%
Net Income (TTM) (Mil) ($94) ($10) 11%
EPS (TTM) ($1.066) ($0.600) 20%
Operating Cash Flow (TTM) (Mil) $324 ($7) 65%
Net Cash Flow (TTM) (Mil) $239 $1 86%
Long-Term Debt (Q1) (Mil) $122 $6 45%
Enterprise Value (Q1) (Mil) $4,747 $408 62%
Valuation LQDA Industry
Median
Percentile
(All Stocks)
P/B na 2.19 na
P/E na 22.1 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.2 na
Ratios LQDA Industry
Median
Percentile
(All Stocks)
Gross Margin 92.7% 69.5% 94%
Net Margin (15.1%) 3.9% 18%
ROA (19.6%) (22.7%) 20%
ROE na (25.0%) na
Liabilities to Assets 103.7% 31.8% 95%
F-Score 6 3 67%

Liquidia Corporation did not pass any screens on 11/13/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors